Achaogen Selected to Present at InsideVenture’s Debut Investor Conference

- March 25-26, Santa Barbara, California -

SAN FRANCISCO, CA, March 23, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced that J. Kevin Judice, Ph.D., chief executive officer and chief scientific officer, will present at InsideVenture’s Debut Conference, March 25-26, 2009 in Santa Barbara, California. Achaogen has been selected from over 170 nominations to be one of 50 top private companies showcased to long-term investors through presentations and 1-on-1 meetings at the invitation only conference. InsideVenture’s Selection Boards includes Founders and Partners of leading venture firms including NEA, Venrock, DCM, Domain, Frazier, Clarus, Oak Investment, Aisling, and Versant. Over 130 investors are represented in the selected companies.

“We are honored to support Achaogen in their private funding efforts through our online platform and at our debut transactional conference in Santa Barbara,” said Mona DeFrawi, chief executive officer of InsideVenture. “InsideVenture was created as a powerful and cost-effective platform to support the companies that grow our economy by facilitating their late stage and pre-IPO financing needs. Structural changes in the capital markets over the past 10 years have blocked the real path to economic growth by challenging the financing of the companies delivering valuable new products, jobs and profits for the world economy. These top 50 companies have invested in innovation, and now InsideVenture is innovating the investment process to support their continued growth.”

“Achaogen is pleased to use InsideVenture’s new financing platform because it provides an efficient means to access and build relationships with a number of high quality private investors,” said Dr. Judice.

InsideVenture Investor Conference – March 25-26, Santa Barbara, California
Achaogen is one of 50 top late-stage private healthcare and technology companies seeking to raise $20-200+M or establish and develop relationships with new investors prior to an eventual IPO. The companies will present their businesses to qualified institutional buyers (QIBs), including mutual fund managers, crossover funds, late stage VC & PE funds and strategic corporate investors. Investors interested in attending the conference may apply for an InsideVenture trial membership; the conference is exclusive to members and by invitation only.  The theme of this year’s conference is “Investing in Innovation: Innovation in Investing”.  Investors should contact InsideVenture today to apply for membership and an invitation to the InsideVenture Investor Conference, March 25-26, 2009 in Santa Barbara, California.

About Achaogen
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of innovative, broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is poised to meet the evolving needs of this market by applying its anticipatory science to develop drugs today that will combat tomorrow’s resistant pathogens. This scientific strategy represents a novel approach to addressing the global bacterial resistance crisis. Achaogen is creating new medicines that anticipate the next wave of anti-bacterial infections, including agents for the underserved Gram-negative infectious disease market and methicillinresistant Staphylococcus aureus (MRSA). Achaogen’s most advanced compound, ACHN-490, one of the company’s next generation aminoglycosides known as neoglycosides, entered the clinic in January 2009, and the company has several other innovative small molecule antibacterial programs nearing clinical development. South San Francisco-based Achaogen is backed by top-tier venture investors and has received substantial non-dilutive funding from NIH, the U.S. Department of Defense, the Wellcome Trust and other sources. Venture capital investors include 5 AM Ventures, ARCH Venture Partners and Domain Associates, Venrock Associates and Versant Ventures. For more information, please visit the company’s website at www.achaogen.com.

About InsideVenture
InsideVenture is an industry sponsored financial marketing utility creating a direct private market platform for institutional and strategic investment in late-stage private companies. InsideVenture’s exclusive vetting and membership requirements connect the best late-stage
venture-backed companies with revered long-term institutional and strategic investors to facilitate late-stage transactions, IPO participation and aftermarket support. InsideVenture is supported by investment leaders and partners like T. Rowe Price, Wasatch Advisors, SVB
Financial Group, NYSE, Alexandria Equities, Intralinks Corporation, New Enterprise Associates, Domain Associates, DCM, Venrock Associates, Versant Ventures, Frazier Healthcare Ventures, Clarus Ventures, and Aisling Capital among others. InsideVenture is based in Menlo Park, California and on the web at www.insideventure.com.

InsideVenture Conference & Membership Contact:
Benjamin Levy, Vice President
650-926-0661
blevy@insideventure.com

InsideVenture Media Contact:
Matthew Stotts
TENOR
415.786.2231
matthew@tenorcom.com

Achaogen Contact:
Sondra Newman, Pure Communications
(617) 877-5687